-- 獨立研究機構CFRA向提供了以下研究報告。 CFRA分析師的觀點摘要如下: DVN第一季調整後每股收益為1.04美元,低於去年同期的1.21美元,比市場預期低0.05美元。產量為83.3萬桶油當量/日,高於2025年第一季的81.5萬桶油當量/日,但比預期低3000桶油當量/日。資本支出為8.48億美元,較預期中位數低6%,推動自由現金流強勁成長至8.16億美元,較上季成長16%。股東於5月4日批准了與Coterra的合併,預計將於5月7日完成,這將是一個重要的催化劑,管理層的目標是到2027年底實現10億美元的年度稅前協同效應。 DVN的業務優化計畫正在加速推進,預計10億美元的年度稅前收益目標將提前實現。特拉華盆地以50.1萬桶油當量/日的產量(佔總產量的60%)為業績奠定了基礎,同時DVN保持了46%的液體/54%的天然氣平衡,使其在併購整合方面處於有利地位。我們預計,合併後,透過計劃中的50億美元以上的股票回購授權和將季度股息提高至每股0.315美元,股東回報將得到提升。公司擁有18億美元的現金儲備,淨負債與EBITDAX比率僅為0.9倍,這些都將為穩健的資產負債表提供支撐。
Related Articles
Simcere Pharmaceutical Receives Chinese Regulatory Approval to Begin Trials of Tumor Drug
Simcere Pharmaceutical (HKG:2096) received Chinese regulatory approval to begin clinical trials of SIM0613, according to a Hong Kong bourse filing Wednesday.The injection is intended to treat advanced solid tumors and is licensed to Ipsen Pharma in regions outside Greater China.
Meitu Records 30% Rise in Paying Subscribers
Meitu (HKG:1357) said the number of paying subscribers using its platform grew 30% year on year to 17.90 million as of end March, according to a Hong Kong bourse filing Wednesday.Paying subscribers for the company's productivity tools grew 53% to 2.34 million, while leisure app subscribers increased 27% to 15.56 million, the firm said.The company's core revenue grew 34.3% year on year to 852 million yuan, while other businesses remained "stable overall."The company's annual recurring revenue for AI-driven productivity apps stood at 580 million yuan as of March, a 56% increase from a year earlier.
Yidu Tech Unit Wins SG$2.3 Million Singapore Healthcare Project
Yidu Tech (HKG:2158) said its subsidiary EVYD Research Private Limited won a contract from Singapore Health Services for the implementation and support of Dr Buddy, according to a Wednesday Hong Kong bourse filing.The total project amount is about SG$2.3 million.